SCHEDULE: State Street Discloses Stake in Janux Therapeutics

State Street Corporation has reported a beneficial ownership of 4.1% in Janux Therapeutics Inc. as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Janux Therapeutics Inc. common stock.
• As of March 31, 2026, State Street Corporation beneficially owns 2,464,017 shares, representing 4.1% of the class.
• The filing indicates shared voting power over 2,373,058 shares and shared dispositive power over 2,464,017 shares.
• State Street Corporation is classified as a 'HC' (likely referring to a holding company or financial institution) and is filing under Rule 13d-1(b).
• Several subsidiaries of State Street Global Advisors are identified as entities that acquired the securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of institutional ownership without specific operational or financial performance data for Janux Therapeutics.

Positives

• State Street Corporation's filing indicates a significant institutional investor's interest in Janux Therapeutics.
• The ownership stake of 4.1% suggests a notable position, though not controlling.

Negatives

• The filing does not contain any negative financial performance indicators or operational challenges for Janux Therapeutics.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks related to Janux Therapeutics' business operations or market position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Janux Therapeutics' future performance.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G from a major entity like State Street Corporation can signal confidence or increased interest in a company's prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the increased institutional interest from State Street Corporation as a positive signal for Janux Therapeutics' potential growth and stability.

Next Steps

• State Street Corporation will continue to hold its shares in Janux Therapeutics, subject to its investment strategies.
• Further filings may be required if State Street Corporation's ownership stake changes significantly.

Key Dates

Keywords

Janux Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, 47103J105